Novartis: approval in paediatric psoriasis

(CercleFinance.com) - Novartis has announced that the European Commission has approved its Cosentyx (secukinumab) for routine first-line treatment of moderate-to-severe plaque psoriasis in children and teenagers from six years to 18 years old.


This approval is based on two international Phase III studies that showed a high efficacy of Cosentyx for a rapid improvement of skin symptoms and the quality of life, with a favourable safety profile up to 52 weeks.

Moderate-to-severe psoriasis affects over 350,000 children worldwide. The Swiss pharmaceutical company has applied for the same approval in several other countries including Australia, Canada, Japan and the US.


Copyright (c) 2020 CercleFinance.com. All rights reserved.